Home PageChelation therapy

Chelation Therapy


Chelation therapy is an intravenous treatment designed to bind heavy metals in the body in order to treat heavy metal toxicity. Proponents claim it also treats coronary artery disease and other illnesses that may be linked to damage from free radicals (reactive molecules).


The benefits of EDTA chelation for the treatment of lead poisoning and excessively high calcium levels are undisputed. The claims of benefits for those suffering from atherosclerosis, coronary artery disease, and other degenerative diseases are more difficult to prove. Reported uses for chelation therapy include treatment of angina, gangrene, diabetic circulation ulcers and blood vessel disease, arthritis, multiple sclerosis, Parkinson’s disease, psoriasis, and Alzheimer’s disease. Improvement is also claimed for people experiencing diminished sight, hearing, smell, coordination, and sexual potency.


The term chelation is from the Greek root word “chele,” meaning “claw.” Chelating agents, most commonly diamine tetraacetic acid (EDTA), were originally designed for industrial applications in the early 1900s. It was not until the World War II era that the potential for medical therapy was realized. The initial intent was to develop antidotes to poison gas and radioactive contaminants. The need for widespread therapy of this nature did not materialize, but more practical uses were found for chelation. During the following decade, EDTA chelation therapy became standard treatment for people suffering from lead poisoning. Patients who had received this treatment claimed to have other health improvements that could not be attributed to the lead removal only. Especially notable were comments from those who had previously suffered from intermittent claudication (due to blocked arteries in legs) and angina. They reported suffering less pain and fatigue, with improved endurance, after chelation therapy. These reports stimulated further interest in the potential benefits of chelation therapy for people suffering from atherosclerosis and coronary artery disease.

If the preparatory examination suggests that there is a condition that could be improved by chelation therapy, and there is no health reason why it shouldn’t be used, then the treatment can begin. The patient is generally taken to a comfortable treatment area, sometimes in a group location, and an intravenous line is started. A solution of EDTA together with vitamins and minerals tailored for the individual patient is given. Most treatments take two to four hours, as the infusion must be given slowly in order to be safe. The number of recommended treatments is usually between 20 and 40. They are given one to two times a week. Maintenance treatments can then be given at the rate of once or twice a month. Maximum benefits are reportedly attained after approximately three months after a treatment series. The cost of therapy is approx $130 – 150/session and is not Medicare funded, but it is a fraction of the cost of an expensive medical procedure like cardiac bypass surgery.


A candidate for chelation therapy should initially have a thorough history and physical to define the type and extent of clinical problems. Laboratory tests will be done to determine whether there are any conditions present that would prevent the use of chelation. Patients who have preexisting hypocalcemia, poor liver or kidney function, congestive heart failure, hypoglycemia, tuberculosis, clotting problems, or potentially allergic conditions are at higher risk for complications from chelation therapy. A Doppler ultrasound may be performed to determine the adequacy of blood flow in different regions of the body.


It is important for people who receive chelation therapy to work with medical personnel who are experienced in the use of this treatment. Treatment should not be undertaken before a good physical, lifestyle evaluation, history, and any laboratory tests necessary are performed. The staff must be forthcoming about test results and should answer any questions the patient may have. Evaluation and treatment should be individualized and involve assessment of kidney function before each treatment with chelation, since the metals bound by the EDTA are excreted through the kidneys.

Although EDTA binds harmful, toxic metals like mercury, lead, and cadmium, it also binds some essential nutrients of the body, such as copper, iron, calcium, zinc, and magnesium. Large amounts of zinc are lost during chelation. Supplements of zinc are generally given to patients undergoing chelation.

Chelation therapy does not replace proper nutrition, exercise, and appropriate medications or surgery for specific diseases or conditions.

Side effects

Side effects of chelation therapy are reportedly unusual, but are rarely serious. Mild reactions may include, but are not limited to, local irritation at the infusion site, skin reactions, nausea, headache, dizziness, hypoglycemia, fever, leg cramps, or loose bowel movements.. Present regimes are safe with no serious side effects or complications reported

Research and general acceptance

EDTA chelation is a highly controversial therapy. The treatment is approved by the United States Food and Drug Administration (FDA) for lead poisoning and seriously high calcium levels. However, for the treatment of atherosclerotic heart disease, EDTA chelation therapy is not endorsed by the American Heart Association (AHA), the FDA, the National Institutes of Health (NIH), or the American College of Cardiology. The AHA reports that there are no adequate, controlled, published scientific studies using currently approved scientific methods to support this therapy for the treatment of coronary artery disease.

There is an extensive trial underway in the US involving 1000’s of people and the results will be available in the next few years. Anecdotal reports are very clear about its positive effects and pooled analysis from Chelatione results of over 70 studies showed positive results in all but one.



Cassileth, Barrie. The Alternative Medicine Handbook. New York: W. W. Norton & Company, Inc., 1998.

Cranton, Elmer. Bypassing Bypass. Virginia: Medex Publishers, Inc., 1997.

Walker, Morton & Shah, Hilandra. Everything you should know about CHELATION THERAPY. Keats Pub. New Canaan, Connecticut 1997


Chappel, Stall. Journal of the Advancement of Medicine 6 (1993): 139-160.


Cranton, Elmer. Chelation therapy. <http://www.drcranton.com